CO6670578A2 - Deposito farmacéutico para 5- fluoro-2- [[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-siopropoxi-1h-pirazol-3il)amino]piridin-3-carbonitrilo - Google Patents

Deposito farmacéutico para 5- fluoro-2- [[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-siopropoxi-1h-pirazol-3il)amino]piridin-3-carbonitrilo

Info

Publication number
CO6670578A2
CO6670578A2 CO13015333A CO13015333A CO6670578A2 CO 6670578 A2 CO6670578 A2 CO 6670578A2 CO 13015333 A CO13015333 A CO 13015333A CO 13015333 A CO13015333 A CO 13015333A CO 6670578 A2 CO6670578 A2 CO 6670578A2
Authority
CO
Colombia
Prior art keywords
fluoro
amino
carbonitrile
pyridin
pyridyl
Prior art date
Application number
CO13015333A
Other languages
English (en)
Inventor
Emily Fuller
Armelle Janini
Philip Alexander Macfaul
Rachel Pugh
Ian Alun Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6670578(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6670578A2 publication Critical patent/CO6670578A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un depósito farmacéutico que comprende (i) 5-fluoro-2- [[(1S) -1- (5-fluoro-2-piridil)etil]amino}-6-[(5-isopropoxi-1H-pirazol-3-il)amino] piridin-3- carbonitrilo o su sal farmacéuticamente aceptable, como un agente farmacéutico (PA) y (ii) un polímero que se degrada para crear un microclima ácido, donde el PA se libera del polímero tras la degradación del polímero.
CO13015333A 2010-07-19 2013-01-28 Deposito farmacéutico para 5- fluoro-2- [[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-siopropoxi-1h-pirazol-3il)amino]piridin-3-carbonitrilo CO6670578A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36540710P 2010-07-19 2010-07-19

Publications (1)

Publication Number Publication Date
CO6670578A2 true CO6670578A2 (es) 2013-05-15

Family

ID=44511084

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13015333A CO6670578A2 (es) 2010-07-19 2013-01-28 Deposito farmacéutico para 5- fluoro-2- [[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-siopropoxi-1h-pirazol-3il)amino]piridin-3-carbonitrilo

Country Status (19)

Country Link
US (2) US20120022110A1 (es)
EP (1) EP2595608A2 (es)
JP (1) JP2013535443A (es)
KR (1) KR20130137592A (es)
CN (1) CN103108627A (es)
AR (1) AR082291A1 (es)
AU (1) AU2011281323A1 (es)
BR (1) BR112013001489A2 (es)
CA (1) CA2804725A1 (es)
CL (1) CL2013000174A1 (es)
CO (1) CO6670578A2 (es)
EC (1) ECSP13012447A (es)
MX (1) MX2013000774A (es)
RU (1) RU2013104639A (es)
SG (1) SG186929A1 (es)
TW (1) TW201208685A (es)
UY (1) UY33517A (es)
WO (1) WO2012010883A2 (es)
ZA (1) ZA201301246B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108871607B (zh) 2018-08-13 2020-01-03 太原理工大学 一种面向分布式光纤拉曼传感器的高精度温度解调方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
KR100367144B1 (ko) * 1997-07-02 2003-01-14 유로-셀티크 소시에떼 아노뉨 관절과 체강(ｂｏｄｙ ｓｐａｃｅ)내에서 연장된 마취
CN100528224C (zh) * 2004-09-27 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 含干扰素α-1b的注射用缓释微球及其制备方法
CN1631362A (zh) * 2004-11-26 2005-06-29 中国科学院上海药物研究所 一种抗肿瘤控释组合物及其制备方法
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
CN1308034C (zh) * 2004-12-27 2007-04-04 中山大学 一种干扰素聚乳酸－羟乙酸共聚物plga微球的制备方法
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
CN100457187C (zh) * 2006-11-10 2009-02-04 中国人民解放军第二军医大学 Vegf缓释注射微球支架及其制备方法和用途
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249

Also Published As

Publication number Publication date
JP2013535443A (ja) 2013-09-12
KR20130137592A (ko) 2013-12-17
SG186929A1 (en) 2013-02-28
EP2595608A2 (en) 2013-05-29
WO2012010883A3 (en) 2012-09-07
MX2013000774A (es) 2013-03-22
RU2013104639A (ru) 2014-08-27
AU2011281323A1 (en) 2013-02-28
TW201208685A (en) 2012-03-01
AR082291A1 (es) 2012-11-28
CA2804725A1 (en) 2012-01-26
ZA201301246B (en) 2014-05-28
US20120022110A1 (en) 2012-01-26
CL2013000174A1 (es) 2013-03-08
BR112013001489A2 (pt) 2016-05-31
WO2012010883A2 (en) 2012-01-26
CN103108627A (zh) 2013-05-15
ECSP13012447A (es) 2013-03-28
UY33517A (es) 2012-02-29
US20140045895A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
DK2925272T3 (da) Lægemiddelopbevarings-, udleverings- og administrationssystem
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY32062A (es) Inhibidores de beta-secretasa
EP2713849A4 (en) SYSTEMS AND METHOD FOR MONITORING A TIME-CONTROLLED LIGHT-FIRMING EXTRACTION OR AN ANALYZER PRESENCE
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
CO6410298A2 (es) Pirimidinas fusionadas
MX362442B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
ECSP13012824A (es) Derivados de (1,2,4)triazolo[4,3-a)quinoxalina como inhibidores de fosfodiesterasas
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
MX350082B (es) Moleculas de entrega selectiva y metodos de uso.
ES2570958T3 (es) Composición para el tratamiento de la fístula
CA2899448C (en) Selective delivery molecules and methods of use
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CL2012002038A1 (es) Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion.
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas